Kidney-Sparing drug combo offers hope for renal pelvic cancer patients
NCT ID NCT07233252
First seen Nov 18, 2025 · Last updated May 12, 2026 · Updated 28 times
Summary
This study tests a combination of two drugs (tislelizumab and nab-paclitaxel) to treat a type of kidney cancer called renal pelvic cancer. The goal is to control the disease while saving the kidney, avoiding the need for full kidney removal. About 35 adults with early-stage cancer that hasn't spread will receive the treatment and be followed for one year to see if their kidney can be spared.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TISLELIZUMAB are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Hospital of Tianjin Medical University
RECRUITINGTianjin, Outside U.S., 300211, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.